交易 bluebird bio, Inc. - BLUE CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
- 所有權
交易條件
价差 | 0.03 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
bluebird bio Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Mar 18, 2024 | 1.43 | 0.01 | 0.70% | 1.42 | 1.53 | 1.36 |
Mar 15, 2024 | 1.41 | 0.09 | 6.82% | 1.32 | 1.44 | 1.29 |
Mar 14, 2024 | 1.32 | -0.04 | -2.94% | 1.36 | 1.37 | 1.29 |
Mar 13, 2024 | 1.38 | 0.06 | 4.55% | 1.32 | 1.44 | 1.31 |
Mar 12, 2024 | 1.33 | -0.10 | -6.99% | 1.43 | 1.43 | 1.31 |
Mar 11, 2024 | 1.39 | -0.18 | -11.46% | 1.57 | 1.64 | 1.36 |
Mar 8, 2024 | 1.48 | 0.02 | 1.37% | 1.46 | 1.63 | 1.44 |
Mar 7, 2024 | 1.43 | -0.02 | -1.38% | 1.45 | 1.49 | 1.39 |
Mar 6, 2024 | 1.44 | 0.00 | 0.00% | 1.44 | 1.52 | 1.34 |
Mar 5, 2024 | 1.37 | -0.04 | -2.84% | 1.41 | 1.49 | 1.37 |
Mar 4, 2024 | 1.52 | -0.04 | -2.56% | 1.56 | 1.58 | 1.43 |
Mar 1, 2024 | 1.54 | 0.15 | 10.79% | 1.39 | 1.65 | 1.39 |
Feb 29, 2024 | 1.37 | -0.30 | -17.96% | 1.67 | 1.72 | 1.34 |
Feb 28, 2024 | 1.67 | -0.10 | -5.65% | 1.77 | 1.85 | 1.62 |
Feb 27, 2024 | 1.73 | 0.21 | 13.82% | 1.52 | 1.90 | 1.46 |
Feb 26, 2024 | 1.44 | 0.17 | 13.39% | 1.27 | 1.50 | 1.26 |
Feb 23, 2024 | 1.23 | 0.03 | 2.50% | 1.20 | 1.30 | 1.16 |
Feb 22, 2024 | 1.17 | 0.13 | 12.50% | 1.04 | 1.18 | 1.04 |
Feb 21, 2024 | 1.08 | 0.00 | 0.00% | 1.08 | 1.12 | 1.04 |
Feb 20, 2024 | 1.09 | 0.08 | 7.92% | 1.01 | 1.11 | 1.01 |
bluebird bio, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Wednesday, March 27, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q4 2023 bluebird bio Inc Earnings Release Q4 2023 bluebird bio Inc Earnings ReleaseForecast(预报) -上一页 - |
Tuesday, May 7, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q1 2024 bluebird bio Inc Earnings Release Q1 2024 bluebird bio Inc Earnings ReleaseForecast(预报) -上一页 - |
Friday, June 14, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 bluebird bio Inc Annual Shareholders Meeting bluebird bio Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 3.597 | 3.662 | 0 | 0 | 54.579 |
收入 | 3.597 | 3.662 | 0 | 0 | 54.579 |
總營業費用 | 290.689 | 594.573 | 559.259 | 562.963 | 626.602 |
銷售/一般/行政費用,總計 | 136.908 | 209.969 | 239.95 | 235.844 | 174.129 |
研究與開發 | 240.764 | 319.946 | 319.309 | 327.119 | 448.589 |
Other Operating Expenses, Total | 2.999 | ||||
營業收入 | -287.092 | -590.911 | -559.259 | -562.963 | -572.023 |
其他,淨值 | 22.699 | -1.748 | 0.319 | -0.684 | 1.961 |
稅前淨收入 | -266.461 | -562.38 | -560.37 | -555.567 | -555.438 |
稅後淨收入 | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
未計算非常項目前的淨收益 | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
淨收入 | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
普通股股東可獲收益 (不含非經常性項目) | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
普通股股東可獲收益 (含非經常性項目) | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
攤薄淨收入 | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
攤薄後加權平均股 | 78.585 | 68.91 | 62.178 | 55.191 | 52.032 |
扣除特別項目的每股攤薄盈利 | -3.39222 | -8.16482 | -9.02338 | -10.0564 | -10.6785 |
每股正常攤薄盈利 | -4.19504 | -7.92145 | -9.02338 | -10.0564 | -10.6785 |
收入成本,共計 | 10.077 | 38.857 | 0 | 0 | 0.885 |
毛利 | -6.48 | -35.195 | 0 | 0 | 53.694 |
利息收入(費用),非經營淨值 | -2.068 | 30.279 | -1.43 | 8.08 | 14.624 |
非常規項目總計 | 0 | -256.74 | -57.639 | -234.586 | |
異常費用(收入) | -97.06 | 25.801 | 0 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 6.89 | 2.381 | 0.063 | 0.071 | 1.519 |
收入 | 6.89 | 2.381 | 0.063 | 0.071 | 1.519 |
收入成本,共計 | 9.564 | 3.376 | 0.021 | 0 | 1.745 |
毛利 | -2.674 | -0.995 | 0.042 | 0.071 | -0.226 |
總營業費用 | 92.187 | -6.056 | -25.372 | 84.852 | 108.919 |
銷售/一般/行政費用,總計 | 40.349 | 37.354 | 30.707 | 33.402 | 36.694 |
研究與開發 | 42.274 | 46.144 | 45.9 | 53.149 | 63.841 |
營業收入 | -85.297 | 8.437 | 25.435 | -84.781 | -107.4 |
利息收入(費用),非經營淨值 | 2.679 | 2.825 | 0.369 | 0.383 | -0.426 |
其他,淨值 | 9.63 | 9.978 | 6.538 | 7.885 | 7.688 |
稅前淨收入 | -72.988 | 21.24 | 32.342 | -76.513 | -100.138 |
稅後淨收入 | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
未計算非常項目前的淨收益 | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
非常規項目總計 | 0 | ||||
淨收入 | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
普通股股東可獲收益 (不含非經常性項目) | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
普通股股東可獲收益 (含非經常性項目) | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
攤薄淨收入 | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
攤薄後加權平均股 | 108.685 | 103.303 | 85.257 | 81.543 | 73.767 |
扣除特別項目的每股攤薄盈利 | -0.67082 | 0.20561 | 0.37806 | -0.9384 | -1.35749 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.67082 | -0.69398 | -0.39959 | -0.95194 | -1.26749 |
Other Operating Expenses, Total | |||||
異常費用(收入) | 0 | -92.93 | -102 | -1.699 | 6.639 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 199.488 | 336.52 | 1215.54 | 1152.17 | 1419 |
現金和短期投資 | 180.327 | 299.503 | 1151.25 | 1106.46 | 1385.3 |
現金等價物 | 113.006 | 161.16 | 317.705 | 327.214 | 402.579 |
短期投資 | 67.321 | 138.343 | 833.546 | 779.246 | 982.725 |
預付的費用 | 8.374 | 25.628 | 37.472 | 32.888 | 19.762 |
總資産 | 554.902 | 593.795 | 1781.25 | 1727.42 | 2242.84 |
物業/廠房/設備,總計 - 淨額 | 291.358 | 101.238 | 346.85 | 337.061 | 246.622 |
物業/廠房/設備,總計 - 總額 | 313.29 | 121.644 | 397.91 | 373.634 | 275.798 |
累計折舊,總計 | -21.932 | -20.406 | -51.06 | -36.573 | -29.176 |
商譽,淨額 | 5.646 | 5.646 | 13.128 | 13.128 | 13.128 |
無形資産,淨額 | 4.868 | 0 | 10.041 | 14.326 | 13.169 |
長期投資 | 1.414 | 97.114 | 122.891 | 131.506 | 506.123 |
其他長期資産,總計 | 52.128 | 53.277 | 72.805 | 79.229 | 44.805 |
流動負債總額 | 128.237 | 152.993 | 203.588 | 223.58 | 146.431 |
應付賬款 | 25.092 | 25.883 | 21.602 | 42.995 | 17.831 |
預提費用 | 100.895 | 123.676 | 149.775 | 136.402 | 96.696 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 2.25 | 3.434 | 32.211 | 44.183 | 30.48 |
負債總額 | 358.559 | 219.518 | 426.196 | 442.431 | 357.774 |
長期債務總額 | 0 | 0 | 0 | 0 | 153.319 |
資本租賃義務 | 0 | 153.319 | |||
其他負債,總計 | 230.322 | 66.525 | 222.608 | 218.851 | 58.024 |
總權益 | 196.343 | 374.277 | 1355.06 | 1284.99 | 1885.07 |
普通股 | 0.83 | 0.711 | 0.665 | 0.554 | 0.547 |
額外實收資本 | 4186.09 | 4096.4 | 4260.44 | 3568.18 | 3386.96 |
留存收益(累計赤字) | -3986.5 | -3719.93 | -2900.55 | -2281.85 | -1498.81 |
其他權益,總計 | -4.07 | -2.911 | -5.505 | -1.893 | -3.627 |
總負債和股東權益 | 554.902 | 593.795 | 1781.25 | 1727.42 | 2242.84 |
已發行普通股總數 | 82.923 | 71.115 | 66.432 | 55.368 | 54.738 |
應收賬款總額,淨額 | 0.4 | 0.4 | 0.019 | ||
其他流動資産,總計 | 10.787 | 11.389 | 26.414 | 12.426 | 13.912 |
長期債務的當前部分/資本租賃 | 0 | 1.424 | |||
應收賬款 - 貿易,淨額 | 0.4 | 0.4 | |||
總庫存 | 0 | ||||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 247.076 | 287.977 | 351.071 | 199.488 | 160.438 |
現金和短期投資 | 174.293 | 245.303 | 318.257 | 180.327 | 139.633 |
現金等價物 | 165.347 | 172.872 | 239.045 | 113.006 | 66.478 |
短期投資 | 8.946 | 72.431 | 79.212 | 67.321 | 73.155 |
應收賬款總額,淨額 | 23 | ||||
應收賬款 - 貿易,淨額 | 23 | ||||
總庫存 | 20.969 | 13.642 | 3.809 | ||
預付的費用 | 11.431 | 13.597 | 13.466 | 8.374 | 8.27 |
其他流動資産,總計 | 17.383 | 15.435 | 15.539 | 10.787 | 12.535 |
總資産 | 613.608 | 663.393 | 692.736 | 554.902 | 520.098 |
物業/廠房/設備,總計 - 淨額 | 304.689 | 313.076 | 278.871 | 291.358 | 300.219 |
物業/廠房/設備,總計 - 總額 | 321.771 | 329.152 | 299.439 | 313.29 | 323.791 |
累計折舊,總計 | -17.082 | -16.076 | -20.568 | -21.932 | -23.572 |
商譽,淨額 | 5.646 | 5.646 | 5.646 | 5.646 | 5.646 |
無形資産,淨額 | 5.368 | 5.49 | 5.613 | 4.868 | |
長期投資 | 0 | 0 | 0 | 1.414 | 1.407 |
其他長期資産,總計 | 50.829 | 51.204 | 51.535 | 52.128 | 52.388 |
流動負債總額 | 158.957 | 135.016 | 115.933 | 128.237 | 126.727 |
應付賬款 | 19.852 | 10.894 | 19.235 | 25.092 | 18.622 |
預提費用 | 121.455 | 118.272 | 91.54 | 100.895 | 105.004 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 17.65 | 5.85 | 5.158 | 2.25 | 3.101 |
負債總額 | 391.072 | 374.374 | 337.996 | 358.559 | 361.241 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 232.115 | 239.358 | 222.063 | 230.322 | 234.514 |
總權益 | 222.536 | 289.019 | 354.74 | 196.343 | 158.857 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 1.071 | 1.065 | 1.064 | 0.83 | 0.829 |
額外實收資本 | 4333.59 | 4328.49 | 4322.02 | 4186.09 | 4181.39 |
留存收益(累計赤字) | -4109.9 | -4038.17 | -3965.26 | -3986.5 | -4018.74 |
其他權益,總計 | -2.227 | -2.364 | -3.086 | -4.07 | -4.63 |
總負債和股東權益 | 613.608 | 663.393 | 692.736 | 554.902 | 520.098 |
已發行普通股總數 | 107.022 | 106.454 | 106.37 | 82.923 | 82.88 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
经营活动产生的现金 | -352.953 | -635.639 | -470.351 | -564.384 | -413.426 |
经营活动产生的现金 | 5.001 | 19.649 | 19.356 | 17.434 | 17.158 |
非现金物品 | -52.254 | 146.105 | 157.838 | 161.673 | 105.801 |
已付现金利息 | 0 | 0 | 0 | 15.494 | |
营运资金的变化 | -39.122 | 17.985 | -28.85 | 46.117 | 19.24 |
投资活动产生的现金 | 250.453 | 562.557 | -84.345 | 507.807 | -679.435 |
资本支出 | -13.208 | -23.003 | -28.986 | -76.252 | -55.737 |
其他投资现金流量项目,总计 | 263.661 | 585.56 | -55.359 | 584.059 | -623.698 |
融资活动产生的现金 | 54.253 | -93.954 | 546.715 | 21.187 | 737.692 |
融资现金流项目 | 0 | -174.284 | 0 | 3.098 | |
股票的发行(报废),净额 | 54.253 | 80.33 | 546.715 | 21.187 | 735.611 |
现金净变化 | -48.247 | -167.036 | -7.981 | -35.39 | -355.169 |
债务的发行(退还),净额 | 0 | -1.017 | |||
Cash Taxes Paid | 0.253 | 0.617 | 0.361 | 0.637 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 21.24 | -266.578 | -298.81 | -222.29 | -122.152 |
Cash From Operating Activities | -86.638 | -352.953 | -296.68 | -219.654 | -125.296 |
Cash From Operating Activities | 1.082 | 5.001 | 3.745 | 2.358 | 1.014 |
Non-Cash Items | -87.074 | -52.254 | 44.053 | 32.613 | 22.606 |
Changes in Working Capital | -21.886 | -39.122 | -45.668 | -32.335 | -26.764 |
Cash From Investing Activities | 82.136 | 250.453 | 147.211 | 131.602 | 69.926 |
Capital Expenditures | -1.1 | -13.208 | -8.1 | -6.836 | -0.857 |
Other Investing Cash Flow Items, Total | 83.236 | 263.661 | 155.311 | 138.438 | 70.783 |
Cash From Financing Activities | 130.456 | 54.253 | 54.368 | 8.043 | 0.009 |
Issuance (Retirement) of Stock, Net | 130.456 | 54.253 | 54.368 | 8.043 | 0.009 |
Net Change in Cash | 125.954 | -48.247 | -95.101 | -80.009 | -55.361 |
Financing Cash Flow Items | 0 | ||||
Cash Taxes Paid | 0.002 |
投資者名稱 | 投資者類型 | 流通股百分比 | 持有股份 | 股份變動 | 持有日期 | 換手率 |
---|---|---|---|---|---|---|
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 15.2947 | 16358130 | -1407416 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.239 | 7742289 | 100261 | 2023-06-30 | LOW |
Tang Capital Management, LLC | Hedge Fund | 6.9029 | 7382827 | -2500000 | 2023-06-30 | MED |
PFM Health Sciences, LP | Hedge Fund | 6.8115 | 7285121 | 1263278 | 2023-06-30 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.1909 | 5551853 | 148970 | 2023-06-30 | LOW |
Granahan Investment Management, Inc. | Investment Advisor | 4.5406 | 4856322 | 3411065 | 2023-06-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.3634 | 4666813 | 1562062 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 2.3372 | 2499715 | 0 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0755 | 2219758 | 121116 | 2023-06-30 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 2.0103 | 2150054 | 739758 | 2023-06-30 | MED |
Columbia Wanger Asset Management, LLC | Investment Advisor | 1.8952 | 2026953 | 0 | 2023-08-31 | MED |
BofA Global Research (US) | Research Firm | 1.8088 | 1934599 | -30674 | 2023-06-30 | LOW |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 1.718 | 1837462 | 129019 | 2023-06-30 | MED |
Frazier Healthcare Partners | Venture Capital | 1.5988 | 1709907 | 269150 | 2023-06-30 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 1.5949 | 1705842 | 90091 | 2023-06-30 | LOW |
Pictet Asset Management (Japan) Ltd. | Investment Advisor | 1.4491 | 1549818 | 763570 | 2023-04-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2948 | 1384820 | -1211649 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.914 | 977570 | 518614 | 2023-06-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.8923 | 954388 | -469533 | 2023-06-30 | MED |
Jane Street Capital, L.L.C. | Research Firm | 0.8913 | 953295 | 439219 | 2023-06-30 | HIGH |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Bluebird Company profile
关于 bluebird bio Inc
bluebird bio, Inc.是一家生物技术公司。 公司主要致力于遗传性疾病基因疗法的研究、开发和商业化。 公司在遗传病方面的基因治疗项目包括B型地中海贫血;LentiGlobin候选产品作为镰状细胞病(SCD)的治疗方法,以及elivaldogene autotemcel(eli-cel)作为脑肾上腺白质营养不良(CALD)的治疗方法。 该公司正在使用慢病毒载体(LVV)平台,定制设计其每一种疗法,以解决疾病的根本原因。 公司正在开发lovotibeglogene autotemcel(lovo-cel),作为SCD患者的一次性治疗,SCD是一种由B-球蛋白基因的单一突变导致产生异常镰状血红蛋白(HbS)的遗传疾病。 betibeglogene autotemcel (beti-cel)的BLA是针对定期接受红细胞(RBC)输血的B型地中海贫血患者。
Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球580,000万多名交易者的一份子,选择利用Capital.com进行交易吧。